Thrombin generation assay modifications needed for its application to monitoring of replacement therapy for haemophilia

Haemophilia. 2021 Jan;27(1):e129-e132. doi: 10.1111/hae.14024. Epub 2020 Sep 8.

Authors

Leonid A Parunov¹, Stepan S Surov^{1

2}, Maitreyi Chattopadhyay¹, Yideng Liang¹, Timothy K Lee¹, Mikhail V Ovanesov¹

Affiliations

¹ Center for Biologics Evaluation and Research (CBER), U.S. Food and Drug Administration, Silver Spring, Maryland, USA.
² Center for Theoretical Problems of Physicochemical Pharmacology, Russian Academy of Sciences, Moscow, Russia.

PMID: 32897618
DOI: 10.1111/hae.14024

No abstract available

Publication types

Letter

MeSH terms

Blood Coagulation
Hemophilia A* / drug therapy
Hemophilia B* / diagnosis
Hemophilia B* / drug therapy
Humans
Thrombin

Substances

Thrombin